Skip to content

A cross sectional study on the impact of scleroderma population after infecting COVID-19 based on online community

A cross sectional study on the impact of scleroderma population after infecting COVID-19 based on online community

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069326
Enrollment
Unknown
Registered
2023-03-13
Start date
2023-03-13
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scleroderma

Interventions

Scleroderma Group:None

Sponsors

Shanghai TCM-integrated Hospital, Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as Scleroderma in Grade III Level A hospital hospital more than 6 months; 2. Patients with a history of COVID-19 infection, who have turned negative for more than one week without serious sequelae; 3. Aged 18-75 years old; 4. Voluntary acceptance of this research plan, good compliance, clear thinking, clear expression, normal language and sensory response. Patients who can understand the specific situation and significance of this study.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of psychiatric diagnosis; 2. Patients with a history of major diseases secondary to other non-systemic sclerosis such as tumor, stroke, severe trauma, etc.

Design outcomes

Primary

MeasureTime frame
infection of COVID-19;Patient Health Questionnaire-9, PHQ-9 score;Generalized Anxiety Disorder, GAD-7 scale score;Seattle Angina Questionnaire, SAQ score;Cochin 17-item Scleroderma Functional, CSF-17 score;

Countries

China

Contacts

Public ContactJiaqian Zhang

Shanghai TCM-integrated Hospital, Shanghai University of TCM

zhangjqdr@foxmail.com+86 135 6448 8599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026